Introduction
============

Intestinal malrotation is a congenital aberrant positioning of the bowel that is usually accompanied with anomalous bowel fixation through mesenteric bands or a lack of fixation in parts of the bowel ([@b1-mmr-22-04-3289]). Intestinal malrotation was first described by William Ladd in 1936 and later classified as non-rotation, mixed or incomplete rotation, reversed rotation, or mesocolic hernia ([@b2-mmr-22-04-3289],[@b3-mmr-22-04-3289]). Typically, ≤ one in 200 newborns are estimated to have asymptomatic rotational anomaly ([@b3-mmr-22-04-3289],[@b4-mmr-22-04-3289]). Symptomatic malrotation affects 1 in 6,000 live births and often occurs in the first few weeks of life, resulting in elevated risk of bowel obstruction, midgut volvulus and necrosis in the bowel ([@b3-mmr-22-04-3289],[@b5-mmr-22-04-3289],[@b6-mmr-22-04-3289]). Currently, upper gastrointestinal (UGI) series is the preferred imaging technique for malrotation diagnosis. Nevertheless, both false positive and false negative interpretations occur, with reported false positive rates of ≤15% ([@b1-mmr-22-04-3289],[@b7-mmr-22-04-3289],[@b8-mmr-22-04-3289]). When the duodenojejunal junction position is ambiguous based on UGI series, further examination is necessary. A barium enema might prove helpful in such cases; however, the first pass of barium through the duodenum is often overlooked ([@b9-mmr-22-04-3289]). The duodenal anatomy is hard to recognize with inadequate amounts of barium, while excessive barium could cause rapid and uncontrolled passage of barium through the duodenum or vague visualization. Moreover, the use of sonography in malrotation diagnosis often requires the opinion of experienced radiologists, who may not always available at most centers ([@b10-mmr-22-04-3289],[@b11-mmr-22-04-3289]). Therefore, the diagnosis of intestinal malrotation is often an intricate and complex process, and a more effective and ideally non-invasive diagnostic method is needed ([@b6-mmr-22-04-3289],[@b11-mmr-22-04-3289],[@b12-mmr-22-04-3289]).

MicroRNAs (miRNAs) are a group of non-coding RNA molecules, usually 19--25 nucleotides long, which are abundantly and stably expressed in plasma and other bodily fluids ([@b13-mmr-22-04-3289],[@b14-mmr-22-04-3289]). Differential expression of specific miRNAs has been identified in numerous diseases, and an increasing body of evidence indicates that miRNAs could serve as promising biomarkers for diagnostic use ([@b15-mmr-22-04-3289]--[@b17-mmr-22-04-3289]). For example, previous studies have identified miRNAs associated with various types of cancer, highlighting an opportunity to use these circulating disease-related miRNAs as biomarkers ([@b18-mmr-22-04-3289],[@b19-mmr-22-04-3289]). In cardiovascular diseases, it was demonstrated that the combined use of multiple miRNAs could improve the predictive efficiency of traditional diagnostic methods ([@b20-mmr-22-04-3289],[@b21-mmr-22-04-3289]). Thus, understanding the potential role of miRNAs in intestinal malrotation may provide invaluable insight into improved diagnostic approaches, as demonstrated in other diseases ([@b22-mmr-22-04-3289]--[@b24-mmr-22-04-3289]).

Previously, a mutation in the forkhead box F1 gene was demonstrated to be associated with intestinal malrotation ([@b25-mmr-22-04-3289]). However, to the best of the authors\' knowledge, no studies have evaluated epigenetic changes during the pathogenesis of intestinal malrotation ([@b26-mmr-22-04-3289]). In the present study, it was hypothesized that the expression of specific miRNAs might be dysregulated in newborns with intestinal malrotation. Thus, the aim of the present study was to determine whether such differentially expressed miRNAs could be used for improved diagnosis of intestinal malrotation.

Materials and methods
=====================

### Study design and sample collection

Ten children with intestinal malrotation (age range, 5 days to month) and ten sex- and age-matched controls (age range, 4 days to 1 month) admitted to The Children\'s Hospital of Nanjing Medical University (Nanjing, China) between February 2018 and July 2019 were enrolled in the present study, and their plasma samples were collected prospectively. Children with immunological disorders, cardiovascular diseases and other congenital digestive tract abnormalities were excluded, as these pathological factors can affect serum miRNA levels. Plasma samples were collected in a plasma separator tube prior to any treatment and stored at −80°C until use. The study was approved by the Institutional Ethics Committee of The Children\'s Hospital of Nanjing Medical University (approval no. 201701025). Written informed consent was obtained from a parent of each patient.

### RNA extraction

Total RNA was extracted from plasma samples using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. In addition, 5 µl of 200 nM cel-miR-39 (Guangzhou RiboBio Co., Ltd.) was added to each sample to serve as an external control ([@b27-mmr-22-04-3289]). RNA concentration and quality was assessed using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.). RNA was stored at −80°C until use.

### Illumina HiSeq sequencing

A total of six plasma samples (three patients with intestinal malrotation and three controls) were used for sequencing. miRNA-seq library was constructed using NEBNext Small RNA kit (NEB, cat. no. E7300S). DNA integrity was measure using an Agilent 2100 Bioanalyzer with the Agilent DNA 1000 kit (Agilent Technologies, Inc.; cat. no. 5067-1504). Sequencing was performed on the Illumina HiseqX platform (Illumina, Inc.; 150 cycles; paired-end). HiSeq X Ten Reagent kit v2.5 (Illumina, Inc.; cat. no. FC-501-25) was used for sequencing. The concentration of DNA was 30--40 nM, which was measured by real-time PCR. Ligation of 5′ and 3′ adaptors was carried out following manufacturer\'s instructions. Small RNAs were amplified by PCR (17 cycles) using adaptor-specific primers according to the manufacturer\'s protocol The PCR products (fragments of \~90 bp) were purified by 8% PAGE. The size distribution of molecules in each sample were evaluated using an Agilent 2100 Bioanalyzer. Subsequently, amplification of the eligible RNAs was conducted to generate the cluster on the flow cell, which was then sequenced using the HiSeq 2000 System (single end; Illumina, Inc.), following the manufacturer\'s instructions. miRNAs were considered to be significantly differentially expressed if P\<0.05 and log~2~ (fold-change) ≥8 for upregulated miRNAs, or log~2~ (fold-change) ≤-8 for downregulated miRNAs in the intestinal malrotation group, compared with the control group. These criteria applied to the average of the three samples.

### Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis

GO functional enrichment analysis (<http://geneontology.org/docs/go-enrichment-analysis/>) and KEGG pathway enrichment analysis (<http://www.genome.jp/kegg/pathway.html>) of DEGs were performed using DIANA TOOLS MirPath version 3 (<http://diana.imis.athena-innovation.gr/DianaTools/index.php>). GO has three functional categories: Molecular function (MF); biological process (BP); and cellular component (CC). P\<0.05 was considered as a statistically significant difference.

### Quantification of plasma miRNA levels using reverse transcription-quantitative PCR (RT-qPCR)

Total RNA extracted from 20 plasma samples (10 patients with intestinal malrotation and 10 controls) was reverse transcribed to cDNA using the PrimeScript™ RT reagent kit (Takara Bio, Inc.), according to the manufacturer\'s instructions. RT-qPCRs were carried out using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd.) on a Light Cycler 480 (Roche Diagnostics) to measure miRNA expression levels. A total of 18 miRNA candidates (15 upregulated and three downregulated miRNAs in intestinal malrotation) were selected for RT-qPCR analysis. Thermocycling conditions consisted of an initial denaturation at 95°C for 10 min, followed by 40 cycles at 94°C for 15 sec and 60°C for 1 min. Relative expression values were normalized against the spike-in cel-miR-39 and analyzed using the 2^−ΔΔCq^ method ([@b28-mmr-22-04-3289]).

### Statistical analysis

Statistical analysis was carried out using GraphPad Prism 8.0 (GraphPad Software, Inc.) and SPSS 23.0 (IBM Corp.). A two-sided unpaired t-test was used to compare differences in miRNA expression between the control and intestinal malrotation groups. Receiver operating curve (ROC) analysis was performed to determine the area under the curve (AUC) of miRNA expression. SPSS 23.0 (IBM Corp.) was used to construct and analyze the curves. The final results were illustrated using GraphPad Prism 8.0 (GraphPad Software, Inc.). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of differentially expressed serum miRNAs in intestinal malrotation

Serum miRNA levels were measured in six plasma samples (three patients with intestinal malrotation and three controls) using high-throughput sequencing. Overall, \~2,588 miRNAs were identified. The profiles of differentially expressed plasma miRNAs are presented as a heat map and a volcano plot in [Fig. 1](#f1-mmr-22-04-3289){ref-type="fig"}. Both the heat map and volcano plot show that patients with intestinal malrotation and healthy controls displayed markedly different plasma miRNA profiles. A total of 28 miRNAs exhibited significant differential expression, of which 21 were upregulated and 7 down regulated in patients with IM, compared with controls ([Table I](#tI-mmr-22-04-3289){ref-type="table"}).

### Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis

GO analysis suggested that the differentially expressed miRNAs were mainly involved in involved in 'skeletal system development', 'axon development' ([Fig. 2A](#f2-mmr-22-04-3289){ref-type="fig"}, [Table II](#tII-mmr-22-04-3289){ref-type="table"}). These miRNAs were mainly localized or exerted their functions in dendrites and the actin cytoskeleton ([Fig. 2A](#f2-mmr-22-04-3289){ref-type="fig"}, [Table III](#tIII-mmr-22-04-3289){ref-type="table"}). Moreover, these miRNAs were involved in 'metal ion transmembrane transporter activity', 'channel activity' and 'substrate-specific channel activity' and other molecular functions ([Fig. 2A](#f2-mmr-22-04-3289){ref-type="fig"}; [Table IV](#tIV-mmr-22-04-3289){ref-type="table"}).

KEGG pathway analysis identified 58 significantly enriched pathways in the sequenced miRNAs. The 10 most enriched pathway terms were 'PI3K-Akt signaling pathway', 'human papillomavirus infection', 'MAPK signaling pathway', 'endocytosis', 'Cushing syndrome', 'gastric cancer', 'estrogen signaling pathway', 'AGE-RAGE signaling pathway in diabetic complications', 'galactose metabolism' and 'vitamin digestion and absorption' ([Fig. 2B](#f2-mmr-22-04-3289){ref-type="fig"}). The most significant KEGG pathway was 'Endocytosis' (KEGG ID, hsa04144), which involved 51 target genes (P=001; [Table V](#tV-mmr-22-04-3289){ref-type="table"}). The network associated was analyzed, which demonstrated TGF-β signaling pathway and endosomal recycling compartment were mainly affected ([Fig. 3](#f3-mmr-22-04-3289){ref-type="fig"}). Thus, GO and KEGG analysis provided novel insights into the underlying mechanism by which plasma miRNAs might participate in the pathogenesis of intestinal malrotation.

### Selection and validation of potential plasma miRNA biomarkers for intestinal malrotation

A total of 18 miRNAs were differentially expressed. Of these, 15 miRNAs were upregulated, including, hsa-miR-1914-3p, miR-6763-5p, miR-185-3p, miR-4738-3p, miR-3131, miR-6797-5p, miR-6740-5p, miR-412-5p, miR-6758-5p, miR-6862-5p, miR-365a-5p, miR-197-5p, miR-6877-5p, let-7 and miR-7976. Moreover, three were downregulated, hsa-miR-194-5p, −144-3p and −93-5p ([Table I](#tI-mmr-22-04-3289){ref-type="table"}) and were selected for further validation. The expression levels of all 18 candidates were measured in a larger sample size (10 patients with intestinal malrotation and 10 controls) by RT-qPCR. In total, nine miRNAs were confirmed to be differentially expressed. Of these, six were upregulated, compared with the control group, including hsa-miR-1914-3p, −6763-5p, −185-3p, −3131, −6740-5p and −6758-5p. In addition, three were downregulated, hsa-miR-194-5p, −144-3p and −93-5p ([Fig. 4](#f4-mmr-22-04-3289){ref-type="fig"}; [Table VI](#tVI-mmr-22-04-3289){ref-type="table"}).

### ROC curve analysis

The sensitivity and specificity of the aforementioned 9 miRNAs as potential diagnostic biomarkers of intestinal malrotation were determined using ROC curve analysis. The AUCs of these miRNAs ranged from 0.727-0.975 ([Fig. 5](#f5-mmr-22-04-3289){ref-type="fig"}; [Table VII](#tVII-mmr-22-04-3289){ref-type="table"}). MiR-1914-3p (AUC, 0.975; 95% CI, 0.913-1.000) and miR-3131 (AUC, 0.975; 95% CI, 0.913-1.000) presented the largest AUCs, followed by miR-185-3p (AUC, 0.958; 95% CI, 0.873-1.000) and miR-6763-5p (AUC, 0.950; 95% CI, 0.856-1.000).

Discussion
==========

Malrotation is a congenital abnormal bowel position within the peritoneal cavity that usually involves both the small and the large bowel ([@b29-mmr-22-04-3289]). The term malrotation encompasses a wide range of rotational and fixation abnormalities of the intestines, from readily apparent omphaloceles in newborns to asymptomatic non-rotation in adults ([@b1-mmr-22-04-3289]). Congenital intestinal non-rotation and incomplete rotation usually concur with a narrow base of the mesentery, which might cause duodenal obstruction and midgut volvulus and manifest as acute symptoms ([@b30-mmr-22-04-3289]). Pediatric patients who do not present acute symptoms but are not diagnosed before adulthood are at risk of developing various chronic symptoms later in life, including vomiting, vague abdominal pain, diarrhea, nausea, early satiety and bloating, dyspepsia and other functional or psychiatric disorders ([@b31-mmr-22-04-3289],[@b32-mmr-22-04-3289]).

Approximately 90% of infants with intestinal malrotation are diagnosed within the first year of life, and \~80% within the first month ([@b33-mmr-22-04-3289]). Common diagnostic tools include UGI, ultrasonography, and barium enema. Although the duodenojejunal junction is usually fixed at the Treitz ligament and functions as a useful landmark, in some cases UGI results may be confusing or hard to interpret, and diagnosis of these cases of malrotation depends on the recognition of anatomic subtleties ([@b8-mmr-22-04-3289],[@b34-mmr-22-04-3289]). Both false positive and false negative findings have been reported ([@b7-mmr-22-04-3289],[@b8-mmr-22-04-3289],[@b35-mmr-22-04-3289],[@b36-mmr-22-04-3289]). Barium enema can help to some extent in some cases, but challenges exist in terms of the quantity of barium administered to children and the observation of the first pass of barium through the duodenum ([@b5-mmr-22-04-3289]). Moreover, the interpretation of ultrasonographical findings can be very subjective, and the presence of an experienced radiologist or technician, who may not always be available at every hospital or medical center, is essential ([@b10-mmr-22-04-3289]).

In the present study, potential diagnostic biomarkers were identified by analyzing plasma miRNA levels in pediatric patients with intestinal malrotation. A profile of differentially expressed miRNAs in the plasma of intestinal malrotation patients was obtained by sequencing plasma miRNAs, and a number of differentially expressed miRNAs were identified, including 21 upregulated and seven downregulated miRNAs. Subsequently, bioinformatics analyses were carried out to investigate the potential involvement of differentially expressed miRNAs in intestinal malrotation.

GO enrichment analysis suggested that these miRNAs were mainly involved in 'metal ion transmembrane transporter activity', 'calcium-dependent protein binding', 'cation channel activity' and 'phospholipid binding'. 'Metal ion transmembrane transporter activity' and 'calcium-dependent protein binding' were the most significantly enriched GO terms with respect to molecular function. Interestingly, it was previously reported that calcium channel-blocking drugs could lead to many developmental abnormalities in *Xenopus* embryos, including malrotation of the gut, possibly through dysregulation of calcium ion antagonism ([@b37-mmr-22-04-3289]). However, the potential link between plasma miRNA levels and calcium ion antagonism in intestinal malrotation requires further study to determine where and how plasma miRNAs interfere with calcium ion. 'Cornification' was the most significantly enriched GO term with respect to biological processes, followed by 'skeletal system development cornification'. A previous study reported a higher frequency of malformations in the skeleton system, including the facial skeleton, the small pelvis, and the upper and lower extremities, among pediatric patients with intestinal malrotation ([@b38-mmr-22-04-3289]). The present results indicated that plasma miRNAs might play a role in this association. The most enriched KEGG pathway was 'endocytosis', which is a critical process in the intestine that is responsible for the endocytic uptake of macromolecules from the gut lumen. For instance, but its role in intestinal malrotation has not yet been studied ([@b39-mmr-22-04-3289],[@b40-mmr-22-04-3289]).

miRNAs have been demonstrated to play a variety of roles in numerous intestinal diseases and several could even function as biomarkers ([@b41-mmr-22-04-3289]--[@b43-mmr-22-04-3289]). Another important finding of the present study was that plasma miRNAs have the potential to serve as circulating biomarkers for intestinal malrotation. Based on the sequencing data and validation by RT-qPCR in a larger number of samples, nine miRNAs were differentially expressed, including six upregulated miRNAs (hsa-miR-1914-3p, −6763-5p, −185-3p, −3131, −6740-5p and −6758-5p) and three downregulated miRNAs (hsa-miR-194-5p, −144-3p and −93-5p). The highest AUCs were obtained for miR-1914-3p, −3131, −185-3p and −6763-5p, suggesting that these miRNAs may serve as diagnostic biomarkers for intestinal malrotation. As a following step, studies with larger sample sizes are necessary to validate the present findings.

In conclusion, a profile of differentially expressed miRNAs in the plasma of patients with intestinal malrotation was identified, and the potential molecular functions associated with these miRNAs were described. Four of the nine confirmed differentially expressed miRNAs have the potential to improve early diagnosis of intestinal malrotation. However, these miRNAs exhibited relatively small 95% CIs, which is a great limitation to our study and requires further confirmation in the future with much larger sample size. These results also suggested that plasma miRNAs play an important role in intestinal malrotation, although this hypothesis requires further investigation.
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![Heat map and volcano plot of significantly dysregulated miRNAs. (A) Heat map and (B) volcano plot of significantly dysregulated miRNAs from the serum of patients with IM. Red indicates upregulated genes and green downregulated genes with P\<0.05. miR/miRNA, microRNA; NC, negative control; IM, intestinal malrotation; DEG, differentially expressed gene; Up, upregulated; Down, downregulated.](MMR-22-04-3289-g00){#f1-mmr-22-04-3289}

![Bioinformatics analysis of the sequencing data. (A) GO enrichment analysis of BPs, CCs and MFs. P-values and the number of genes under each term are shown on the x-axis. GO term descriptions are presented along the y-axis. (B) Bubble graph of Kyoto Encyclopedia of Genes and Genomes enrichment results. The gene ratio of each pathway is indicated on the x-axis. Number of genes involved in each pathway proportional to the size of the bubbles. The color of the bubbles represent the P-values. GO, Gene Ontology; CC, cellular component; BP, biological process; MF, molecular function.](MMR-22-04-3289-g01){#f2-mmr-22-04-3289}

![Detailed view of the 'endocytosis' network. Each node represents a key transporter or enzyme. The red nodes indicate miRNA with significantly expression, while the green notes represent miRNAs with no significant change in expression.](MMR-22-04-3289-g02){#f3-mmr-22-04-3289}

![Expression levels of 18 candidate miRNAs in the serum of patients with IM and matched controls. miRNA/miR, microRNA; IM, intestinal malrotation. \*P\<0.05; \*\*P\<0.01, \*\*\*P\<0.001, vs. control.](MMR-22-04-3289-g03){#f4-mmr-22-04-3289}

![Receiver operating characteristic curves of selected dysregulated miRNAs. Expression of nine candidate miRNAs was assessed using reverse transcription-quantitative PCR. The corresponding AUCs are presented in the diagrams. miRNA/miR, microRNA; AUC, area under the curve.](MMR-22-04-3289-g04){#f5-mmr-22-04-3289}

###### 

Dysregulated miRNAs in plasma from patients with intestinal malrotation and controls.

  miR               log~2~ (FC)   P-value      Expression
  ----------------- ------------- ------------ ---------------
  hsa-miR-1914-3p   21.2605       0.00053635   Upregulated
  hsa-miR-6763-5p   9.8136        0.00066362   Upregulated
  hsa-miR-194-5p    −11.6088      0.00076538   Downregulated
  hsa-miR-144-3p    −10.8903      0.00124557   Downregulated
  hsa-miR-93-5p     −10.6228      0.00204004   Downregulated
  hsa-miR-185-3p    9.6254        0.00209648   Upregulated
  hsa-miR-4738-3p   10.1860       0.00284375   Upregulated
  hsa-miR-3131      10.0151       0.00290713   Upregulated
  hsa-miR-6797-5p   9.9124        0.00399543   Upregulated
  hsa-miR-6740-5p   9.6671        0.00463324   Upregulated
  hsa-miR-412-5p    9.6234        0.00487532   Upregulated
  hsa-miR-6758-5p   9.3378        0.00625270   Upregulated
  hsa-miR-16-2-3p   −7.0390       0.00726665   Downregulated
  hsa-miR-6862-5p   8.7506        0.00897906   Upregulated
  hsa-miR-365a-5p   8.8099        0.00986631   Upregulated
  hsa-miR-197-5p    8.6241        0.01019434   Upregulated
  hsa-let-7d-5p     −6.4675       0.01114899   Downregulated
  hsa-miR-148b-3p   −5.8861       0.01219763   Downregulated
  hsa-miR-6877-5p   8.3920        0.01254641   Upregulated
  hsa-let-7i-3p     8.3746        0.01255295   Upregulated
  hsa-miR-7976      8.4149        0.01268761   Upregulated
  hsa-miR-4507      7.4372        0.01375498   Upregulated
  hsa-miR-7-5p      6.3143        0.02523047   Upregulated
  hsa-miR-4326      6.1695        0.02722018   Upregulated
  hsa-miR-181a-3p   6.6420        0.03291677   Upregulated
  hsa-miR-7854-3p   7.2962        0.03293265   Upregulated
  hsa-miR-532-3p    5.6365        0.03647876   Upregulated
  hsa-miR-128-3p    −5.7314       0.04537403   Downregulated

miR, microRNA; FC, fold-change.

###### 

Top 10 significantly enriched GO biological processes.

  GO term      Description                               P-value      Count
  ------------ ----------------------------------------- ------------ -------
  GO:0070268   Cornification                             0.00000056   36
  GO:0001501   Skeletal system development               0.00000277   104
  GO:0061564   Axon development                          0.00000467   100
  GO:0007409   Axonogenesis                              0.00000507   93
  GO:0048562   Embryonic organ morphogenesis             0.00000752   66
  GO:0048675   Axon extension                            0.00000985   31
  GO:0048705   Skeletal system morphogenesis             0.00002872   51
  GO:0048568   Embryonic organ development               0.00002935   88
  GO:0090066   Regulation of anatomical structure size   0.00009987   92
  GO:0019233   Sensory perception of pain                0.00010642   27

GO, Gene Ontology.

###### 

Top 10 significantly enriched GO cellular components.

  GO term      Description                      P-value      Count
  ------------ -------------------------------- ------------ -------
  GO:0005796   Golgi lumen                      0.00007119   29
  GO:0045095   Keratin filament                 0.00038711   26
  GO:0015629   Actin cytoskeleton               0.00054521   87
  GO:0030425   Dendrite                         0.00086110   92
  GO:0016324   Apical plasma membrane           0.00093914   59
  GO:0031902   Late endosome membrane           0.00094567   30
  GO:0060205   Cytoplasmic vesicle lumen        0.00123996   66
  GO:0031983   Vesicle lumen                    0.00134049   66
  GO:0016323   Basolateral plasma membrane      0.00140855   44
  GO:0031225   Anchored component of membrane   0.00158692   35

GO, Gene Ontology.

###### 

Top 10 significantly enriched GO molecular functions.

  GO term      Description                                    P-value      Count
  ------------ ---------------------------------------------- ------------ -------
  GO:0046873   Metal ion transmembrane transporter activity   0.00032224   88
  GO:0048306   Calcium-dependent protein binding              0.00068622   18
  GO:0005261   Cation channel activity                        0.00070680   64
  GO:0005543   Phospholipid binding                           0.00075808   74
  GO:0005244   Voltage-gated ion channel activity             0.00140047   43
  GO:0022832   Voltage-gated channel activity                 0.00140047   43
  GO:0022836   Gated channel activity                         0.00187551   65
  GO:0030506   Ankyrin binding                                0.00233200     8
  GO:0015267   Channel activity                               0.00245557   86
  GO:0022838   Substrate-specific channel activity            0.00251147   81

GO, Gene Ontology.

###### 

Top 10 significantly enriched KEGG pathways.

  KEGG pathway   Description                                            P-value      Count
  -------------- ------------------------------------------------------ ------------ -------
  hsa04144       Endocytosis                                            0.00132301   51
  hsa05165       Human papillomavirus infection                         0.00253633   64
  hsa04933       AGE-RAGE signaling pathway in diabetic complications   0.00411644   24
  hsa04915       Estrogen signaling pathway                             0.00688242   30
  hsa00052       Galactose metabolism                                   0.00689000   10
  hsa04010       MAPK signaling pathway                                 0.00724133   56
  hsa04151       PI3K-Akt signaling pathway                             0.00865405   65
  hsa05226       Gastric cancer                                         0.01159650   31
  hsa04934       Cushing syndrome                                       0.01168848   32
  hsa04977       Vitamin digestion and absorption                       0.01228429     8

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Relative expression of nine candidate miRNAs validated by reverse transcription-quantitative PCR from patients with IM and controls.

  miRNA         Controls   Patients with IM   P-value                                                  Fold change
  ------------- ---------- ------------------ -------------------------------------------------------- -------------
  miR-1914-3p   4.552      15.17              0.0001^[c](#tfn8-mmr-22-04-3289){ref-type="table-fn"}^   3.333
  miR-6763-5p   6.422      16.99              0.0002^[c](#tfn8-mmr-22-04-3289){ref-type="table-fn"}^   2.646
  miR-185-3p    3.923      25.02              0.0092^[b](#tfn7-mmr-22-04-3289){ref-type="table-fn"}^   6.378
  miR-3131      4.868      32.54              0.0006^[c](#tfn8-mmr-22-04-3289){ref-type="table-fn"}^   6.684
  miR-194-5p    1.183      0.571              0.0170^[a](#tfn6-mmr-22-04-3289){ref-type="table-fn"}^   0.483
  miR-6740-5p   0.522      1.479              0.0470^[a](#tfn6-mmr-22-04-3289){ref-type="table-fn"}^   2.833
  miR-144-3p    0.628      0.401              0.0449^[a](#tfn6-mmr-22-04-3289){ref-type="table-fn"}^   0.639
  miR-6758-5p   0.349      0.493              0.0061^[b](#tfn7-mmr-22-04-3289){ref-type="table-fn"}^   1.413
  miR-93-5p     1.783      0.881              0.0272^[a](#tfn6-mmr-22-04-3289){ref-type="table-fn"}^   0.494

P\<0.05

P\<0.01

P\<0.001 vs. control. miR/miRNA. microRNA; IM, intestinal malrotation. The values in controls and Patients with IM columns represent the relative expression values.

###### 

The respective AUCs of nine candidate miRNAs.

  miRNA         AUC     Standard error   Asymptotic significance   Asymptotic 95% CI
  ------------- ------- ---------------- ------------------------- -------------------
  miR-1914-3p   0.975   0.032            \<0.001                   0.913-1.000
  miR-6763-5p   0.950   0.048            0.001                     0.856-1.000
  miR-185-3p    0.958   0.044            0.002                     0.873-1.000
  miR-3131      0.975   0.032            \<0.001                   0.913-1.000
  miR-194-5p    0.763   0.128            0.062                     0.512-1.000
  miR-6740-5p   0.789   0.115            0.034                     0.564-1.000
  miR-144-3p    0.739   0.116            0.079                     0.512-0.966
  miR-6758-5p   0.847   0.106            0.016                     0.639-1.000
  miR-93-5p     0.790   0.102            0.028                     0.590-0.991

miR/miRNA, microRNA; AUC, area under the curve.

[^1]: Contributed equally
